Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-01-18
2005-01-18
Epps-Ford, Janet L. (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C536S023100, C536S023500
Reexamination Certificate
active
06844325
ABSTRACT:
Compositions and methods for the therapy and diagnosis of cancer, such as breast cancer, are disclosed. Compositions may comprise one or more breast tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a breast tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as breast cancer. Diagnostic methods based on detecting a breast tumor protein, or mRNA encoding such a protein, in a sample are also provided.
REFERENCES:
patent: 5215926 (1993-06-01), Etchells, III et al.
patent: 5240856 (1993-08-01), Goffe et al.
patent: 5891857 (1999-04-01), Holt et al.
patent: 5986170 (1999-11-01), Subjeck
patent: WO 8906280 (1989-07-01), None
patent: WO 9116116 (1991-10-01), None
patent: WO 9207243 (1992-04-01), None
patent: WO 9629430 (1996-09-01), None
patent: WO 9821331 (1998-05-01), None
patent: WO 9833915 (1998-08-01), None
patent: WO 9854963 (1998-12-01), None
patent: WO 9909155 (1999-02-01), None
patent: WO 0008210 (2000-02-01), None
patent: WO 0043420 (2000-07-01), None
patent: WO 0060076 (2000-10-01), None
patent: WO 0073801 (2000-12-01), None
patent: WO 0137779 (2001-05-01), None
patent: WO 0147959 (2001-07-01), None
patent: WO 0151628 (2001-07-01), None
patent: WO 200147959 (2001-07-01), None
patent: WO 0157270 (2001-08-01), None
patent: WO 0259377 (2002-08-01), None
Gura (Science, 1997, vol. 278, pp. 1041-1042).*
Hartwell et al. (Science, 1997, vol. 278, pp. 1064-1068).*
GenBank Accession No. AL049911 Nordsiek et al. Oct. 22-1999.*
W. French Anderson, Human gene therapy. Nature, vol. 392, Supplemental, pp. 25-30 (1998).*
GenBank Accession No. AF269087. Mar. 28, 2001.
GenBank Accession No. AAK27325. Mar. 28, 2001.
GenBank Accession No. AC069200, May 24, 2000.
Sulston et al., “Toward a complete human genome sequence.”Genome Research8(11):1097-1108, 1998.
GenBank Accession No. AL157387, Feb. 18, 2000.
GenBank Accession No. AC036170, Apr. 9, 2000.
Jäger, D. et al, “Identification of a Tissue-specific Putative Transcription Factor in Breast Tissue by Serological Screening of a Breast Cancer Library,”Cancer Research61(5): 2055-2061, Mar. 1, 2001.
GenBank Accession No. AI687645, May 27, 1999.
GenBank Accession No. AQ280806, Nov. 22, 1998.
Genseq (Derwent) Accession No. AAV90219, Feb. 15, 1999.
Genseq Database (Thomson Derwent), Accession No. AAL25059, Dec. 7, 2001.
Chang and Shu, “Current status of adoptive immunotherapy of cancer,”Critical Reviews in Oncology/Hematology22(3):213-228, Apr. 1996.
Cheever and Chen, “Therapy with cultured T cells: principles revisited,”Immunological Reviews,157: 177-194, 1997.
Cheever et al., “Potential uses of interleukin 2 in cancer therapy,”Immunobiol,172:365-382, 1986.
Chen et al., “T-cells for tumor therapy can be obtained from antigen-loaded sponge implants,”Cancer Research54(4):1065-1070, Feb. 15, 1994.
Cole et al., “Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigent,”Cancer Research,55:748-752, Feb. 15, 1995.
Durrant L., “Cancer vaccines,”Anti-Cancer Drugs,8:727-733, 1997.
Eshhar Z., “Tumor-specific T-bodies: toward clinical application,”Cancer Immunol Immnother,54:131-136, 1997.
Hwu et al., “In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes,”Cancer Research,55:3369-3373, Aug. 1, 1995
Porter-Jordan and Lippman, “Overview of the biologic markers of breast cancer,”Breast Cancer8:(1):73-100, Feb. 1994.
Wei et al., “Protection against mammary tumor growth by vaccination with full-length, modified humanErbB-2DNA,”Int. J. Cancer,81:748-754, 1999.
GenBank Accession No. AA864891, Feb. 20, 1998.
GenBank Accession No. AA398925, Apr. 25, 1997.
Geneseq Accession No. V84525 (Dec. 10, 1998).
Stratagene 1991 product catalog, Prime-It™ Random Labeling Kit, catalog No. 300387, p. 66.
Dillon Davin C.
Harlocker Susan L.
Jiang Yuqiu
Mitcham Jennifer L.
Xu Jiangchun
Corixa Corporation
Epps-Ford Janet L.
Seed IP Law Group PLLC
LandOfFree
Compositions for the treatment and diagnosis of breast... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for the treatment and diagnosis of breast..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for the treatment and diagnosis of breast... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3366982